Skip to main content
. 2019 May 22;6:113. doi: 10.3389/fmed.2019.00113

Figure 3.

Figure 3

Frequency of LAG3 expression on CD4+ and CD8+ T cells. (A) The mean percentage of CD4+ T cells expressing LAG3 in non-responders responders to pembrolizumab (B) The mean percentage of CD8+ T cells expressing LAG3 in non-responders responders to pembrolizumab (C) Boxplot of mean frequency of LAG3 on CD4+ and CD8+ T cells per patient per cycle.